The main purpose of this study is to assess whether LY3857210 is safe and efficacious in relieving chronic low back pain (CLBP). This trial is part of the chronic pain master protocol (H0P-MC-CPMP) which is a protocol to accelerate the development of new treatments for chronic pain.
1 Primary · 7 Secondary · Reporting Duration: Baseline, Up to Week 12
125 Total Participants · 2 Treatment Groups
Primary Treatment: LY3857210 · Has Placebo Group · Phase 2
Age 18+ · All Participants · 9 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: